Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Natus Medical Incorporated : Board of Directors Strengthens Governance and Focuses on Growth

10/14/2021 | 08:31am EST
  • Establishes Environmental, Social & Governance Committee
  • Transitions Quality & Compliance Committee to Innovation & Quality Committee
  • Names Thomas J. Sullivan Senior Independent Director

PLEASANTON, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company’s Board of Directors established an Environmental, Social, and Governance (ESG) committee and transitioned the role of the Quality & Compliance Committee to the Innovation & Quality committee on September 30th, 2021.

The Innovation & Quality committee will provide oversight of the Company’s focus on accelerating growth through product and process innovation and quality. Natus’ success with investments in research and development to advance patient care, coupled with compliance with quality systems and regulatory requirements related to product safety and efficacy are critical to the achievement of the Company’s strategic growth objectives. Dr. Bryant Moore will chair the Innovation & Quality committee.

The ESG committee will enable the Board to ensure ESG risks and opportunities are integrated into the Company’s strategy; provide oversight of the Company’s on-going commitment to sustainability, human capital development, health & safety, data security, diversity & inclusion, and other ESG pillars; and champion transparency in ESG reporting for shareholders. Alice Schroeder will chair the ESG committee.

“My fellow Board members and I are excited that these two committees heighten the Board’s focus on ESG, Innovation and Quality. These are cornerstones of growth and our efforts to create long-term shareholder value. We look forward to collaborating with Jonathan and the Natus Management Team to continue many existing best practices and implement opportunities to improve at all levels of the Company,” said Joshua Levine, Chairman of the Board. Mr. Levine added, “I would also like to thank Tom Sullivan for assuming the additional responsibilities as Senior Independent Director. With his board and management experience, he is a valuable resource and sounding board for myself and our Directors.”

“The foundation of our business and products centers on improving patients' lives, which is core to our social responsibility and sustainability. Innovating and improving the quality of our products enables Natus to make an impact and contribute to society. We have made noteworthy progress in our ESG initiatives in recent years and recognize that further progress in this area is a journey. We look forward to working with our Board to increase the transparency of our accomplishments and to broaden our sustainability in the future,” said Jonathan Kennedy, President and Chief Executive Officer of Natus.

About Natus Medical Incorporated

Natus Medical Incorporated improves patient outcomes using the most comprehensive product solutions, depth of training and continuing customer care when diagnosing and treating central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical Incorporated can be found at https://natus.com.

Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700

Primary Logo

Source: Natus Medical Incorporated

2021 GlobeNewswire, Inc., source Press Releases

11/05NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Resu..
11/04NATUS MEDICAL : Q3 Earnings Snapshot
11/04Natus Medical Announces Third Quarter 2021 Financial Results - Form 8-K
11/04Natus Medical Posts Higher Q3 Adjusted Earnings, Revenue; Narrows Full-Year Revenue Out..
11/04GUIDANCE : (NTUS) NATUS MEDICAL INCORPORATED Expects Fiscal Year 2021 EPS Range $1.13 - $1..
11/04GUIDANCE : (NTUS) NATUS MEDICAL INCORPORATED Expects Q4 EPS Range $0.41 - $0.46
11/04Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q3 EPS $0.28, vs. Street Est o..
11/04Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q3 Revenue $113.9M, vs. Street..
11/04Natus Medical Announces Third Quarter 2021 Financial Results
11/04Natus Medical Incorporated Reports Earnings Results for the Third Quarter and Nine Mont..
More news
Financials (USD)
Sales 2021 471 M - -
Net income 2021 23,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 33,4x
Yield 2021 -
Capitalization 791 M 791 M -
Capi. / Sales 2021 1,68x
Capi. / Sales 2022 1,63x
Nbr of Employees 1 420
Free-Float 98,4%
Duration : Period :
Natus Medical Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATUS MEDICAL INCORPORATED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 1
Last Close Price 23,41 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jonathan A. Kennedy President, Chief Executive Officer & Director
Benjamin Drew Davies Chief Financial Officer & Executive Vice President
Joshua H. Levine Non-Executive Chairman
D. Christopher Chung Chief Medical Officer & VP-Regulatory Affairs
Ivan Pandiyan Vice President-Research & Development
Sector and Competitors